Secaucus-Based Quest Diagnostics Fined $13 Million For Alleged Kickback Violations
Quest Diagnostics (DGX) agreed to pay a $13 million fine to settle allegations it violated anti-kickback laws by offering doctors and executives free perks, including Giants tickets, to induce business referrals between 2013 and 2022, according to U.S. prosecutors.
How this was made

The 30-second read
Why it matters
The settlement resolves allegations spanning 2013‑2022 and includes a $13 M civil penalty, highlighting compliance risks in the health‑care services industry.
Market read
First disclosure of a material enforcement action against a mid‑cap health‑care services firm, introducing compliance risk and modest financial impact.
What to watch
Potential for further investigations or additional penalties if other violations are uncovered.
Background
Quest Diagnostics, a leading U.S. laboratory testing company, was charged with offering illegal kickbacks to physicians and executives via free Giants stadium events, violating the Anti‑Kickback Statute.
Ticker impact
Quest Diagnostics settled a $13 million anti‑kickback fine, the first public disclosure of the enforcement action.
downward pressure as investors price in the fine and potential future regulatory scrutiny
A $13 M fine is material for a mid‑cap health‑care services firm and signals heightened enforcement risk, which typically depresses the stock.
Market effects
May raise compliance costs and scrutiny for other lab‑testing and health‑care service providers.
Limited to U.S. health‑care services sector; no broader regional effect.
Minimal global impact; primarily a U.S. regulatory matter.
Counterpoint
The fine is relatively small versus Quest's revenue, so the market may overreact; the stock could rebound quickly.
Key entities
- companyQuest Diagnostics, Inc.
U.S. lab‑testing services provider, ticker DGX.
- government_officialU.S. Attorney Robert Frazer
Announced the settlement on behalf of the Department of Justice.


